Inoue Takeshi, Kusumi Ichiro, Yoshioka Mitsuhiro
Department of Psychiatry, Hokkaido University, Graduate School of Medicine, Sapporo, Japan.
Curr Drug Targets CNS Neurol Disord. 2002 Oct;1(5):519-29. doi: 10.2174/1568007023338987.
The serotonin transporter is most well known as the site of action of the serotonin reuptake inhibitors, which were initially developed as antidepressants, but now are the most widely used agents in the treatment of many additional neuropsychiatric and related disorders. The discovery that the serotonin transporter gene possesses a functional polymorphism within the promoter region led to many studies examining this polymorphism in individuals with different neuropsychiatric disorders. These observations raise the possibility of developing a new class of agents with different therapeutic and side effect profiles than conventional drugs. This overview of recent studies of the serotonin transporters attempts to open new areas for discussion and define concepts not yet comprehensively reviewed.
血清素转运体最为人所知的是血清素再摄取抑制剂的作用位点，这些抑制剂最初是作为抗抑郁药开发的，但现在是治疗许多其他神经精神疾病及相关病症最广泛使用的药物。血清素转运体基因在启动子区域存在功能性多态性这一发现，引发了许多针对患有不同神经精神疾病个体的该多态性研究。这些观察结果增加了开发一类与传统药物具有不同治疗和副作用特征的新型药物的可能性。本文对血清素转运体近期研究的概述试图开辟新的讨论领域，并界定尚未得到全面综述的概念。
